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Abstract
Background: Tollip is a ubiquitously expressed protein, originally described as a modulator of the IL-1R/TLR-NF-κB
signaling pathways. Although this property has been well characterized in peripheral cells, and despite some
evidence of its expression in the central nervous system, the role of Tollip in neuroinflammation remains poorly
understood. The present study sought to explore the implication of Tollip in inflammation in the substantia nigra
pars compacta, the structure affected in Parkinson’s disease.
Methods: We first investigated Tollip distribution in the midbrain by immunohistochemistry. Then, we addressed
TLR4-mediated response by intra-nigral injections of lipopolysaccharide (LPS), a TLR4 agonist, on inflammatory
markers in Tollip knockout (KO) and wild-type (WT) mice.
Results: We report an unexpectedly high Tollip immunostaining in dopaminergic neurons of the mice brain.
Second, intra-nigral injection of LPS led to increased susceptibility to neuroinflammation in Tollip KO compared to
Tollip WT mice. This was demonstrated by a significant increase of tumor necrosis factor alpha (TNF-α), interleukin 1
beta (IL-1β), interleukin 6 (IL-6), and interferon gamma (IFN-γ) messenger RNA (mRNA) in the midbrain of Tollip KO
mice upon LPS injection. Consistently, brain rAAV viral vector transduction with a nuclear factor kappa B (NF-κB)-
inducible reporter gene confirmed increased NF-κB activation in Tollip KO mice. Lastly, Tollip KO mice displayed
higher inducible NO synthase (iNOS) production, both at the messenger and protein level when compared to LPS-
injected WT mice. Tollip deletion also aggravated LPS-induced oxidative and nitrosative damages, as indicated by
an increase of 8-oxo-2′-deoxyguanosine and nitrotyrosine immunostaining, respectively.
Conclusions: Altogether, these findings highlight a critical role of Tollip in the early phase of TLR4-mediated
neuroinflammation. As brain inflammation is known to contribute to Parkinson’s disease, Tollip may be a potential
target for neuroprotection.
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Background
Neuroinflammation is thought to be an important con-
tributor to the pathogenesis of Parkinson’s disease (PD)
[1, 2]. Indeed, the presence of pro-inflammatory cyto-
kines in postmortem brain samples from PD patients
[3], microglial activation evidenced in patients brain by
PET scan [4], alteration in the composition of lympho-
cyte populations in patients’ blood [5], and activation of
the innate immune surveillance system [6] as well as a
genetic association with the HLA-DRA locus (coding for
major histocompatibility complex II molecules) [7, 8]
strongly support this hypothesis. Chronic inflammation is
thought to cause the degeneration of dopaminergic neu-
rons [9, 10] as shown by findings in toxin-induced [11]
and genetic models of PD [12, 13]. Interestingly, the emer-
ging concept of a decisive role of microglia priming in the
pathogenesis of neurodegenerative diseases supports a
role for acute inflammation in neurodegeneration [14, 15].
Enzymes associated with oxidative (i.e., COX-1 and
COX-2) and nitrosative stresses (i.e., iNOS) have also
been involved in neuronal vulnerability in PD [16, 17].
Furthermore, due to their high iron content [18] and re-
duced glutathione levels [19], dopaminergic neurons are
thought to be particularly susceptible to reactive oxygen
species released by activated microglia.
Lipopolysaccharides (LPS), endotoxins found in the
outer membrane of gram-negative bacteria, were sug-
gested to play a role as an environmental trigger of
PD [20, 21]. LPS signal through Toll-like receptors
(TLR), a family of receptors involved in pathogen rec-
ognition and host defense. More precisely, LPS acti-
vate the nuclear factor kappa B (NF-κB) inflammatory
pathway via TLR4 binding. A single systemic [13, 20] or
intracerebral [22, 23] LPS injection replicates neuroin-
flammation features typically observed in PD, such as
microglia activation and cytokine and iNOS production,
associated to a chronic progression of dopaminergic
neuron degeneration.
The Toll-interacting protein (Tollip) is a ubiquitously
expressed protein, first identified in 2000 through two-
hybrid screening using IL-1 receptor accessory protein
as the bait [24]. The authors showed that Tollip forms a
constitutive complex with the interleukin-1 receptor-
associated kinase 1 (IRAK1). Upon interleukin 1 beta
(IL-1β) stimulation, this complex is recruited, leading to
the dissociation of Tollip from IRAK1 which transmits
the IL-1β-induced signal. In addition, Tollip participates
in the endolysosomal degradation of the IL-1R [25]. Ac-
cordingly, Tollip overexpression impaired IL-1β-induced
activation of NF-κB [24], suggesting an inhibitory role in
inflammatory signaling. Two subsequent in vitro studies
showed that Tollip decreased Toll-like receptor 4 and 2
(TLR4 and TLR-2)-mediated inflammation by directly
interacting with these receptors, supporting a pivotal
role in the innate immune response [26, 27]. Accord-
ingly, Tollip KO mice showed an increased susceptibility
to dextran sulfate sodium-induced colitis [28].
Tollip immunomodulatory properties have been
mainly investigated at the peripheral level and only lim-
ited studies have been conducted in the central nervous
system. However, the brain has been described as the
third region that displays the highest Tollip messenger
RNA (mRNA) densities in human [29]. In addition, a
tissue-based map of human proteome indicates that the
cerebral cortex may display the highest density of Tollip
protein, together with the epididymis and pancreas [30].
A limited number of observations suggest a potential
role of Tollip in the brain. A microarray study reports
downregulation of Tollip mRNA together with an upreg-
ulation of microglia- and perivascular macrophage-
activating genes in brains of aging- and Alzheimer’s
disease patients [31]. In addition, increased Tollip ex-
pression has been associated with a better outcome in a
mouse model of stroke [32] whereas another group re-
ported a deleterious effect of Tollip neuronal expression
in a mouse model of cerebral ischemia/ reperfusion [33].
Finally, an in vitro study showed that the phosphatase
and tensin homolog (PTEN)-induced putative kinase 1
(PINK1), well-known to be linked to an early-onset form
of familial Parkinson’s disease (PD), binds Tollip [34].
The authors proposed that PINK1 stimulates IL-1β-
induced signaling via suppression of Tollip inhibitory
action. Despite these observations, a role of Tollip in the
modulation of inflammation in the central nervous sys-
tem has never been explored.
The Tollip gene contains six exons, three isoforms in
the mouse (Tollip.a, .b, and .c) and four in humans
(TOLLIP.A, .B, .C, and .D) resulting from alternative tran-
scripts. These isoforms are highly conserved between the
two species for some variants (94% between Tollip.a and
TOLLIP.A and 92% between Tollip.c and TOLLIP.D) [35]
(for review [36]). Furthermore, in the brain of C57BL/6J
mice, the canonical Tollip.a mRNA is abundantly
expressed and has been found in neurons, astrocytes,
microglia, and endothelial cells at the seventh post-natal
day [37], making the C57BL/6J mice suitable models to in-
vestigate the role of Tollip in the central nervous system.
The potential role of Tollip in the substantia nigra sus-
ceptibility to inflammation has never been evaluated. In
the current study, we aimed at investigating (i) whether
the Tollip protein is expressed in the substantia nigra
and (ii) whether Tollip deletion (using Tollip knockout
mice) may enhance LPS-mediated neuroinflammation.
Methods
Animals
All procedures and methods were approved by the
Cantonal Veterinary Service for animal experimentation
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(SCAV-EXPANIM; authorization #VD2388.3). The ani-
mals had access to food and tap water ad libitum with a
constant 12-h light/dark cycle. C57BL/6J Tollip knock-
out (KO) and wild-type (WT) mice were generously pro-
vided by Michel Maillard (Service of Gastroenterology
and Hepatology, Department of Medicine, Lausanne
University Hospital, Lausanne, Switzerland). After hav-
ing observed that some of these mice carried a mutation
on the alpha-synuclein gene, strongly linked to neurode-
generation and neuroinflammation in PD, we back-
crossed mice onto the C57BL/6J RccHSD background
strain in order to guarantee that all mice are alpha-
synuclein +/+. Genetic backgrounds were checked by
genotyping according to previously described protocols
[38]. A total of 66 mice were used in this study accord-
ing to the repartition described into the figure legends.
Since our aim was to recapitulate pathogenic events re-
lated to PD, we have used middle-aged mice, i.e., at least
9 months old. Due to constraints in transgenic mice
breeding, in order to work with age-matched groups for
each experiment, we sometimes had to use animals of
different sexes.
Plasmids
The NF-κB-inducible self-complementary rAAV plasmid
pSC-NF12d1-eGFP has been previously described [39].
Briefly, it contains a chimeric promoter consisting in a
minimal CMV promoter flanked by 12 copies of the
NF-κB responsive sequence. The pSC-NF12d1-eGFP-
CMV-mCherry, a plasmid expressing enhanced green
fluorescent protein (eGFP) under the control of the
NF-κB-inducible promoter and constitutively express-
ing the mCherry, was constructed in order to allow
controlling stereotactic injections.
Viral vector
The NF-κB-inducible rAAV vector was produced by
triple co-transfection of HEK-293T cells (thirty 10-cm
plates seeded 24 h before transfection with 5 × 106 cells)
with (i) the pSC-NF12d1-eGFP-CMV-mCherry vector
plasmid (4 μg/plate), (ii) a plasmid carrying the AAV
serotype 2 Rep gene (Rep2) and a serotype 9 Cap gene
harboring a mutation in a surface tyrosine (pXR9-2Y-F)
which reduces viral particle proteosomal degradation
(a kind gift from D. Dalkara [40]) (2 μg/plate), and
(iii) an adenoviral helper plasmid (pAd-Helper; Stratagene)
(5 μg/plate).
Fifty hours post transfection, the medium was dis-
carded and the cells were harvested by low-speed centri-
fugation and resuspended in Tris pH 8.0, NaCl 0.1 M.
After 3 cycles of freezing/thawing, the lysate was clari-
fied by 30-min centrifugation at 10,000 g, treated with
benzonase (50 units/mL, Sigma) at 37 °C for 30 min,
and centrifuged at 10,000 g for 30 min to eliminate the
residual debris. The virus was further purified by iodixa-
nol gradient, buffer exchange, and microconcentration
according to a previously described method [41] except
the chromatography step which was omitted due to its
poor recovery for AAV9. For clarity purposes, this viral
vector has been designated hereafter as rAAV9-NRE-
eGFP. The genomic titer of the recombinant virus was
evaluated using real-time PCR as previously described
[42]. The titer was 5 × 1013 viral genomes (vg)/mL.
Stereotactic injections
Mice were anesthetized with ketamine 100 mg/kg
(Ketasol, Graeub AG) and xylazine 10 mg/kg (Rompun®,
Bayer) solutions and immobilized in the stereotactic
frame. Animals received unilateral infusion of 1 μL of
LPS at a concentration of 0.1 μg/μL (Sigma; Escherichia
coli 026:B6) diluted in Dulbecco’s phosphate-buffered sa-
line (DPBS) (Biowhittaker®, Lonza) solution. LPS from E.
coli origin have a conically shaped lipid A portion and
act as a specific ligand of the TLR4 [43]. Stereotaxic co-
ordinates used were AP - 2.8 mm, ML - 1.3 mm, and DV
- 4.5 mm, according to Bregma for LPS and AAV injec-
tions. The injection rate was 0.5 μL/min for LPS injection
and 0.2 μL/min for rAAV injection. The needle (34 Gauge)
was left in place for additional 5 min before removal. Con-
trol animals received 1 μL of DPBS. The animals were
sacrificed 6 h after LPS injection.
Real-time reverse transcription polymerase chain reaction
(RT-qPCR)
Tissue collection
Six hours after unilateral LPS injection, mice were eu-
thanized with an overdose of pentobarbital (30 mg/mL
in 0.9% NaCl, Esconarkon®). The brain was removed and
dissected on ice using stainless steel brain matrix
(Stoelting Co, USA) and single-edge blades. The ventral
part of the midbrain containing the substantia nigra pars
compacta (SNc) was collected on three coronal sections
at 1-mm intervals (Additional file 1: Figure S2b). The
samples were immediately frozen in liquid nitrogen and
stored at −80 °C.
RNA extraction and cDNA preparation
Total RNA was extracted from tissue samples using
RNeasy® Kit (Qiagen) following manufacturer’s instruc-
tions. Quantity and purity of samples were assessed by
absorbance measurement with a NanoDrop spectropho-
tometer (Thermo Fisher Scientific, USA).
The reverse transcription reaction was carried out
using the High-Capacity cDNA Reverse Transcriptase
kit as already described [44], using reagents and proto-
cols from Thermo Fisher. Thermocycling conditions
were the following: 25 °C for 10 min, 37 °C for 120 min,
85 °C for 5 min, and a final step at 4 °C ad infinitum.
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Quantitative PCR
Semi-quantitative real-time PCR were carried out by
ABI PRISM 7700 Detection system (ABI, Foster City,
CA, USA) using the SYBR® Select Master Mix (Life
Technologies, USA) according to the manufacturer’s
protocols. For mRNA quantification of eGFP (green
fluorescent protein) 4 ng of total complementary DNA
(cDNA) was loaded per reaction, and 2.4 ng/reaction
was used for detection of IL-1β and inducible nitric
oxide synthase (iNOS). For mRNA quantification of
glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
β-actin, glial fibrillary acidic protein (GFAP), and neuro-
filament H (NFH), 0.4-ng total cDNA per reaction was
used. Real-time PCR was performed in a total volume of
10 μL of SYBR® Green Master Mix (ABI, Foster City,
CA, USA) containing 150 μM of forward and reverse
primers for eGFP and 300 μM for all other genes.
Thermocycling conditions were 50 °C for 2 min, 95 °
C for 10 min, and 40 cycles of 15 s 95 °C and 1 min
of 60 °C, following by a dissociation stage. Gene spe-
cific primers used are listed in Table 1. The standard
curve model was used to calculate the mRNA expres-
sion relative to a serial dilution of a pool comprising
all samples. Both β-actin and GAPDH genes were
used as internal controls for each sample and all re-
actions were run in technical triplicates. Post-PCR
melting curves were analyzed to ensure primer speci-
ficity. For each sample, mRNA values were normal-
ized by the value given by the housekeeping gene (β-
actin + GAPDH)/2 that was similar between all
groups.
Immunohistochemistry
Mice were perfused transcardially with PBS pH 7.4
(Bichsel AG) followed by ice-cold 4% paraformaldehyde
in PBS pH 7.4 (PF4). Brains were post-fixed in PF4 over-
night at 4 °C, cryoprotected during two successive days
in 20 and 30% sucrose, and gradually frozen in isopen-
tane/dry ice. Coronal sections (30 μm thick) were cut
using a cryostat (Leica CM1850) and stored in anti-
freeze medium (composed by glycerol, ethylene glycol,
PBS, and water) at −20 °C.
Sections were washed in 10-mM Tris-buffered saline
pH 7.6 (TBS). Non-specific binding was blocked using
5% bovine serum albumin (BSA, Sigma-Aldrich, USA) in
TBS containing 0.5% of Triton-X100 (Sigma-Aldrich,
USA) (THST). Sections were incubated overnight at
4 °C with the primary antibody in 1% BSA/THST followed
by an incubation with secondary antibodies in THST for
1 h at room temperature. Slices were then mounted on
microscope slides with Vectashield (Vector Laboratories,
Burlingame, CA, USA) and stored at 4 °C in the dark. The
labeling analyses were performed on three sections at the
level of the SNc for each individual.
The co-immunostaining of the endogenous Tollip pro-
tein and the tyrosine hydroxylase enzyme (TH) was per-
formed using a rabbit polyclonal antibody against the
full-length Tollip protein (1:50; ab187198, Abcam)
followed by a secondary donkey anti-rabbit antibody
(1:1000; A2106, Molecular Probes) and a mouse anti-TH
(1:1000; MAB318, Millipore) followed by a goat anti-
mouse antibody (1:1000; A-11005, Molecular Probes).
Oxidative and nitrosative stresses were assessed using a
mouse monoclonal anti-8-oxo-dG (1:350; AMS Biotech-
nology, Bioggio-Lugano) and a mouse monoclonal anti-
nitrotyrosine (1:1000; Chemicon International) antibody,
respectively. Microgliosis was evaluated using a rat
monoclonal anti-CD68 (1:1500; Abcam) and a goat poly-
clonal anti-Iba1 (1:1000; Abcam) antibody. Finally, iNOS
Table 1 Mouse primers used for real-time qPCR analysis
Gene Sequences of primers
β-Actin Forward 5′-GCCCTGAGGCTCTTTTCCAG-3′
Reverse 5′-TGCCACAGGATTCCATACCC-3′
CD68 Forward 5′-TTCTGCTGTGGAAATGCAAG-3′
Reverse 5′-AGAGGGGCTGGTAGGTTGAT-3′
GAPDH Forward 5′-TGTGGATGGCCCCTCTGGAA-3′
Reverse 5′-TCAGATGCCTGCTTCACCAC-3′
GFAP Forward 5′-CCAGCTTACGGCCAACAGT-3′
Reverse 5′-TGGTTTCATCTTGGACTTCTG-3′
IFN-γ Forward 5′-TGGCTCTGAAGGATTTTCATC-3′
Reverse 5′-TCAACTGGCATAGATGTGGAAGAA-3′
IL-1β Forward 5′-TCGAGGCCTAATAGGCTCATCT-3′
Reverse 5′-GCTGCTTCAGACACTTGCACAA-3′
IL-6 Forward 5′-TGTTCTCTGGGAAATCGTGGAA-3′
Reverse 5′-GCAAGTGCATCATCGTTGTTCA-3′
IL-10 Forward 5′-ACCTGCTCCACTGCCTTGCT-3′
Reverse 5′-GGTTGCCAAGCCTTATCGGA-3′
iNOS Forward 5′-CATTGGAAGTGAAGCGTTTCG-3′
Reverse 5′-CAGCTGGGCTGTACAAACCTT-3′
NFH Forward 5′-CACCAAGGAGTCACTGGAG-3′
Reverse 5′-TGCTGAATAGCGTCCTGGTA-3
TNF-α Forward 5′-CCTCTTCTCATTCCTGCTTGTGG-3′
Reverse 5′-GGCCATTTGGGAACTTCTCATC-3′
eGFP Forward 5′-CAAAGACCCCAACGAGAAGC-3′
Reverse 5′-CTTGTACAGCTCGTCCATGC-3′
Arg-1 Forward 5′-GAACACGGCAGTGGCTTTAAC-3′
Reverse 5′-TGCTTAGCTCTGTCTGCTTTGC-3′
CD32 Forward 5′-AATCCTGCCGTTCCTACTGATC-3′
Reverse 5′-GTGTCACCGTGTCTTCCTTGAG-3′
CD206 Forward 5′-TCTTTGCTTTCCAGTCTCC-3′
Reverse 5′-TGACACCCAGCGGAATTTC-3′
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was measured with a rabbit polyclonal anti-iNOS (1:500;
Novus Biological) and NeuN with a mouse monoclonal
anti-NeuN (1:2500; Millipore).
Image analysis
Images were acquired with a Zeiss Confocal Microscope
equipped with 310, 320, 340, and 363 Plan-NEOFLUAR
objectives. All parameters were controlled with LSM510
software. For quantification of 8-oxo-dG, iNOS, and 3-
NT immunostainings, images were acquired with a ×40
objective, at a resolution of 1024 × 1024 pixels. In each
animal, quantification has been made on two fields per
section, on three 30-μm-thick sections at the level of
SNc. Analysis has been made with IMARIS 7.3 software
(Bitplane AG, Switzerland). Results are expressed as
number of positive cells/section or as a mean of fluores-
cence intensity/section. For Tollip immunostaining,
quantification has been performed using a ×20 magnifi-
cation. Analysis was performed using ImageJ v1.4
(National Institute of Health, USA).
IL-1β ELISA
All mice underwent unilateral injection of 0.1-μg LPS
according to the protocol described in the “Stereotactic
injections” section. Six hours later, midbrain extracts
from ipsilateral and contralateral side relative to the
injection have been homogenized in Tper solution
(Thermo Scientific), containing phosphatase and prote-
ase inhibitor cocktail (Roche). IL-1β enzyme-linked im-
munosorbent assay (ELISA) has been performed on
60 μg of total protein, using the kit Bioscience cat # 88-
7013 according to the manufacturer’s instructions.
Statistical analysis
Data analyses and graphs were performed using
GraphPad Prism 6 software for Windows (GraphPad
Software Inc., San Diego, CA, USA). For mRNA expres-
sion, ELISA, and immunohistochemistry analysis, com-
parisons were performed by two-way ANOVA followed
by Tukey’s post hoc test.
Results were expressed in the text as mean ± SEM, and
statistical significance was established for a P value ≤0.05.
Results
Tollip protein is highly expressed in dopaminergic
neurons
Unexpectedly, the percentage of Tollip-immunopositive
cells relative to the DAPI-positive cells in the substantia
nigra pars compacta (SNc) (32.0 ± 3.5%) was 10- and 2-
fold higher than those found respectively in the hippo-
campus (3.0 ± 0.6%) and the cortex (13.7 ± 0.9%) (Fig. 1a).
Tollip immunostaining displayed the typical shape of the
SNc/ventral tegmental (VTA) area (Fig. 1b). It should be
noted that this was similarly observed both in male and
female middle-aged mice. The co-staining with anti-TH
antibody showed in addition that Tollip protein is
particularly abundant in dopaminergic neurons, as
98.3 ± 0.3% of TH-positive cells also express Tollip
(Fig. 1b). This novel observation points to a potential
role of Tollip in dopaminergic neurons. However,
Tollip is also detected albeit at a lower level, outside
the SNc in cells not labeled by anti-TH antibodies
(Additional file 2: Figure S1a, b; see arrows). The
identity of these cells remains to be determined. As
expected, no Tollip staining was observed in Tollip
KO mice (Additional file 2: Figure S1c).
Since an increase of Tollip protein detection after LPS
stimulation of immune cells in vitro has been previously
described [45], we tested whether Tollip expression
could be increased after LPS injection in the midbrain of
Tollip WT mice. Brains were analyzed at 6 h post - LPS
injection. The pattern of Tollip protein expression was
not modified by LPS (0.1 μg) treatment as compared
with the non-injected side (Additional file 1: Figure S2a).
Furthermore, quantification of the Tollip mRNA by RT-
qPCR after injection of increasing LPS doses confirmed
that Tollip gene expression in the midbrain was not stim-
ulated by LPS (Additional file 1: Figure S2b).
Effect of LPS (0.1 μg) on cytokines mRNA expression in
the midbrain of Tollip-deficient mice
Our goal was to evaluate the effect of Tollip deletion on
the early neuroinflammatory phase induced by an intra-
nigral LPS injection.
First, increasing LPS doses were unilaterally injected in
the midbrain of adult Tollip WT mice and the expres-
sion of pro-inflammatory cytokines evaluated 6 h later
by RT-qPCR. As shown in Additional file 3: Figure S3, a
LPS dose-dependent increase of IL-1β, interleukin 6 (IL-
6), and tumor necrosis factor alpha (TNF-α) mRNA ex-
pression was observed.
Since our goal was to investigate whether Tollip defi-
ciency could exacerbate the effect of the LPS injection,
we wanted to avoid using a saturating LPS dose which
could have possibly masked the effect of Tollip deletion.
Therefore for further analyses, a submaximal LPS dose
of 0.1 μg was chosen.
The basal and LPS-induced patterns of cytokine ex-
pression in the brain of aged Tollip WT and Tollip KO
mice were then compared. In the absence of inflamma-
tory challenge, no difference was observed between
Tollip WT and KO mice, suggesting that the absence of
Tollip does not induce a spontaneous inflammation in
the brain (Fig. 2, black bars). As expected, LPS intra-
nigral injection increased the level of transcription of all
cytokines tested (Fig. 2, gray bars). However, a differen-
tial increase in Tollip WT versus Tollip KO mice was
observed for most of the cytokines. Indeed, in Tollip
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WT mice, although the mRNA expression of IL-1β,
IL-6, IFN-γ, TNF-α, and IL-10 was increased respect-
ively 6-, 9-, 3-, 10-, and 3-fold in response to LPS,
this effect did not reach significance, except for TNF-α
(Fig. 2a). In contrast, in Tollip KO mice, LPS elicited a sig-
nificant increase of all cytokines: 40-, 19-, 6-, 14-, and 6-
fold respectively as compared with PBS-injected mice (P
< 0.05 for IL-1β, IL-6, IFN-γ, IL-10, and P < 0.001 for
TNF-α). However, the difference between LPS-injected
side in Tollip KO and Tollip WT mice did not reach sig-
nificance. IL-18 was not altered in any condition (data not
shown).
In order to evaluate whether differences in tran-
script levels were also detectable at the protein level,
we investigated whether Tollip deletion had any im-
pact on IL-1β abundance upon intra-nigral LPS injec-
tion (Fig. 2b). IL-1β concentration in midbrain extracts
from injected and non-injected sides has been evaluated
by ELISA. Consistently with our prior data, whereas
the LPS-induced IL-1β increase did not reach statis-
tical significance in WT mice (P = 0.1), it was signifi-
cant in Tollip KO mice (P < 0.001). However, direct
comparison of protein abundance between Tollip WT
and KO mice failed to reach significance (184 ± 74 pg/mg
(Tollip WT) versus 324 ± 55 pg/mg (Tollip KO), P = 0.17,
Fig. 2b).
NFH (neurofilament) mRNA was not altered in any
condition, suggesting that the early-phase inflammatory
response did not result in neuronal toxicity (data not
shown).
In conclusion, genetic deletion of Tollip did not affect
baseline inflammatory cytokine pattern, but led to in-
creased cytokine mRNA expression upon low-dose LPS
injection in the substantia nigra.
Fig. 1 Tollip is highly expressed in dopaminergic neurons. a Representative Tollip (in green) and DAPI staining (in blue) in 10-month-old female
Tollip WT mice. Up - position of the analyzed sections in the Paxinos Atlas [84]. Inset shows the substantia nigra pars compacta (SNc), the
hippocampus (hipp), and the cortex (ctx) analyzed below. Magnification = ×63. Scale bar = 10 μm. Bar graphs below represent the number
of Tollip-positive cells relative to DAPI-positive cells. (n = 3 WT mice); **P < 0.01; ***P < 0.001; one-way ANOVA, Holm–Sidak’s post hoc test.
b Representative Tollip (in green) and tyrosine hydroxylase (TH) (in red) immunostainings and DAPI staining (in blue) in the SNc of 9-month-old
male Tollip WT mice. Magnification = ×20. Scale bar = 50 μm. White insets show the region photographed on the right, at high magnification (×63);
scale bar = 50 μm. Bar graph indicates that 98.3 ± 0.3% of TH-positive cells display also Tollip immunostaining and 88.3 ± 6.3% of Tollip-positive
cells are TH immunopositive
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Tollip KO mice display a higher NF-κB activation in an
inflammatory context
The observed altered cytokine response upon LPS chal-
lenge in Tollip KO mice suggests that Tollip is involved
in the regulation of NF-κB activity upon LPS challenge
in the brain. In order to investigate whether a higher
NF-κB activation is observed in the absence of Tollip, a
NF-κB-inducible rAAV9-NRE-eGFP viral vector was
injected in the SNc of Tollip WT (n = 5) and Tollip KO
mice (n = 5), 2 weeks before LPS challenge (Fig. 3). Six
hours after infusion of LPS (0.1 μg), a higher amount of
eGFP mRNA in the midbrain of Tollip KO mice was
measured, as compared to WT mice (2.5-fold, P < 0.05)
(Fig. 3a). eGFP mRNA amount tended to correlate with
Fig. 2 Inflammatory mediators are increased in the midbrain of Tollip-deficient mice 6 h after LPS intra-nigral injection. a Eleven-month-old
female mice underwent PBS (1 μL) or LPS (0.1 μg in 1 μL) injection (n = 7 and n = 8 respectively for WT mice and n = 6 and n = 12 respectively for
the Tollip KO mice). mRNA amounts in midbrain extracts are normalized by β-actin and GAPDH. b IL-1β protein quantification by ELISA on 60 μg
of midbrain protein extracts from the injected (LPS 0.1 μg) and non-injected sides. n = 5 for WT and 7 for KO 11-month-old mice. Box-and-whisker
graphs show median, min., and max. values and 25th and 75th percentiles. Plots represent individual values and means are represented as a “+.”
*P < 0.05; **P < 0.01; ***P < 0.001 versus PBS for a. and versus non-injected side for b. Two-way ANOVA followed by a Tukey’s post hoc test
Fig. 3 Tollip KO mice display a higher NF-κB-activation. Thirteen-month-old male mice underwent intra-nigral injection of rAAV9-NRE-eGFP
(5 × 108 viral genomes) followed by LPS (0.1 μg) injection 2 weeks later. Analyses were performed at 6 h post-injection of LPS (n = 5 mice per
group). eGFP mRNA amounts in midbrain extracts were normalized by β-actin and GAPDH. a Results are represented as box and whiskers that
show median, min., and max. values, 25th and 75th percentiles. Plots represent individual values and means are represented as a “+.” *P < 0.05
versus WT mice using a Mann–Whitney test. b–c Graph shows correlation between eGFP mRNA and IL-1β mRNA (b) and iNOS mRNA (c) in the
injected side of Tollip KO (empty square) and WT (filled square) mice. The r squared was obtained using Pearson’s correlation
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IL-1β mRNA (P = 0.08, Fig. 3b) and correlated with
iNOS mRNA (P < 0.05, Fig. 3c). This result shows that
Tollip KO mice display a higher NF-κB activation than
Tollip WT mice.
LPS-induced iNOS expression is significantly increased in
the midbrain of Tollip-deficient mice
We next wanted to address whether the observed in-
creased NF-κB activity was associated with induction of
inducible nitric oxide synthase (iNOS), another NF-κB
target gene [46] that is related to PD neuropathology
[16] (Fig. 4). As for cytokine mRNA measurements, sub-
maximal LPS doses (0.1 μg) were not sufficient to sig-
nificantly increase iNOS mRNA in Tollip WT mice,
whereas it was in Tollip KO mice (by 10-fold as com-
pared with PBS-injected group, P < 0.001, Fig. 4a). In
Tollip KO mice, this increase was 2.6-fold larger than in
WT mice (P < 0.05).
In order to confirm this observation, we assessed
iNOS protein expression by immunohistochemistry of
brain tissue from mice subjected to LPS (0.1 μg) stereo-
tactic injection (Fig. 4b). In both Tollip WT and KO
mice, the number of iNOS-positive cells was higher in
the ipsilateral (LPS-injected) side than in the contralat-
eral side (P < 0.01 for WT mice and P < 0.001 for KO
mice, Fig. 4c). This effect was specific to LPS and not
due to the surgery as demonstrated by the absence of
iNOS immunostaining in PBS-injected midbrains
(Additional file 4: Figure S4). The number of iNOS-
positive cells was 58 ± 11 in LPS-injected side in WT
mice versus 90 ± 6 in Tollip KO mice, confirming that
Tollip KO mice displayed an increased iNOS expression
level as compared to WT mice (P < 0.01). Surprisingly,
the quantification in the side contralateral to the LPS
injection revealed also a higher number of iNOS-
positive cells in KO mice (n = 56 ± 2) than in WT mice
((n = 37 ± 4), P < 0.05). This effect could possibly be at-
tributed to an overall higher reactivity of the whole brain
in response to the unilateral LPS injection in Tollip KO
mice.
Effect of Tollip deletion on protein nitrosylation
iNOS increase has been demonstrated to lead to a high
level of nitric oxide (NO) production [47]. In the pres-
ence of oxidative stress, NO may produce peroxynitrite
radicals, a powerful oxidant that is responsible for nitro-
sylation of proteins. In order to further evaluate the im-
pact of iNOS increase a quantification of nitrotyrosine, a
commonly accepted marker of nitrosative stress found
to be increased in PD patients CSF and serum [48], was
performed (Fig. 5a). As expected, LPS induced an
increase of nitrotyrosine immunostaining in Tollip WT
(P < 0.05) and in Tollip KO mice (P < 0.001), as com-
pared with the contralateral side. In the LPS-injected
side, fluorescence intensity of the nitrotyrosine immuno-
staining was 4-fold increased in Tollip KO mice versus
Tollip WT mice (P < 0.001, Fig. 5b). As for iNOS quanti-
fication, nitrotyrosine staining in the side contralateral
to the LPS injection was higher in Tollip KO than in
Tollip WT mice (P < 0.001). These data suggest that
Tollip KO mice are highly predisposed to peroxynitrite
formation.
Effect of Tollip deletion on oxidative stress
In order to validate the hypothesis of a high level of oxida-
tive stress in Tollip KO mice, 8-oxo-2′-deoxyguanosine
(8-oxo-dG), a common marker of oxidized DNA, has been
measured in the midbrain (Fig. 6a). Six hours after LPS
Fig. 4 iNOS is increased in the midbrain of Tollip-deficient mice 6 h after LPS intra-nigral injection. a Eleven-month-old female mice underwent
PBS (1 μL) or LPS (0.1 μg in 1 μL PBS) injection (n = 7 and n = 8 respectively for WT mice and n = 6 and n = 12 respectively for Tollip KO mice).
mRNA amounts in midbrain extracts were normalized by β-actin and GAPDH. *P < 0.05 versus WT mice and ###P < 0.001 versus PBS. b Representative
iNOS immunostaining in contralateral and ipsilateral side of the LPS (0.1 μg) injection, in WT and Tollip KO 15-month-old male mice.
Magnification = ×40. Scale bar = 30 μm. c Quantification of iNOS-positive cells, performed on two fields in the injected area, on three sections per
animal (n = 4 mice in WT and 5 mice in KO group). **P < 0.01 versus WT mice and ##P < 0.01 and ###P < 0.001 versus non-injected side. Box and whiskers
show median, min., and max. values, 25th and 75th percentiles. Plots represent individual values and means are represented as a “+.” Two-way ANOVA
followed by a Tukey’s post hoc test
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injection, 8-oxo-dG immunoreactivity was mainly ob-
served in the cytoplasm, suggesting 8-oxo-dG accumula-
tion in mitochondrial DNA in WT mice (P < 0.05) as well
as in KO mice (P < 0.01). Quantification showed that
fluorescence intensity was significantly increased in KO
mice, on both sides, ipsilateral and contralateral to the
LPS injection (P < 0.001 and P < 0.01 respectively, Fig. 6b).
This result suggests that Tollip KO mice are more suscep-
tible to oxidative stress, as revealed by increased DNA oxi-
dation in response to a pro-inflammatory challenge than
WT mice.
Effect of Tollip deletion on early-phase glial activation
As TLR4 and iNOS are mainly expressed in astrocytes
and macrophages [49–52], we hypothesized that exces-
sive glial activation may account for the high oxidative
and nitrosative stress in Tollip-deficient mice. A series
of microglial markers have been measured at the tran-
scriptional level using qPCR analysis (Fig. 7a) and at the
protein level using immunohistochemistry (Fig. 7b, c).
Moreover, as it is widely accepted that activated micro-
glia exert dual functions, i.e., pro-inflammatory (M1)
and anti-inflammatory (M2); we also evaluated whether
Fig. 5 Nitrotyrosine immunostaining is increased in the midbrain of Tollip-deficient mice 6 h after LPS intra-nigral injection. a. Representative
nitrotyrosine immunostaining in non-injected and LPS (0.1 μg) - injected side in WT and Tollip KO 15-month-old male mice. Magnification = ×40.
Scale bar = 30 μm. b Quantification of fluorescence intensity performed on two fields at the injected area, on three sections per animal (n = 4 in
WT and 5 mice in KO group). Box and whiskers show median, min., and max. values, 25th and 75th percentiles. Plots represent individual values
and means are represented as a “+.” #P < 0.05; ###P < 0.001 versus non-injected side and ***P < 0.001 versus WT mice. Two-way ANOVA followed by
a Tukey’s post hoc test
Fig. 6 8-oxo-2′-deoxyguanosine (8-oxo-dG) immunostaining is increased in midbrain of Tollip-deficient mice 6 h after LPS intra-nigral injection.
a Representative 8-oxo-DG immunostaining in the non-injected and LPS (0.1 μg)-injected side in WT and Tollip KO 15-month-old male mice.
Magnification = ×40. Scale bar = 30 μm. b Quantification of fluorescence intensity performed on two fields in the injected area, on three sections
per animal (n = 4 in WT and 5 mice in KO group). Box and whiskers show median, min., and max. values, 25th and 75th percentiles. Plots represent
individual values and means are represented as a “+.” #P < 0.05; ##P < 0.01 versus non-injected side and **P < 0.01; ***P < 0.001 versus WT mice.
Two-way ANOVA followed by a Tukey’s post hoc test
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Tollip deletion may induce a shift toward one of these
two phenotypes. We measured Iba1 which is a widely
used marker of microglial activation, CD32 and CD68
which are associated with M1 phenotype, and Arg1
and CD206 which are considered as M2 phenotype
markers [53].
LPS is known to elicit an “M1-type” response [54].
However, none of the M1-associated mRNA markers
were significantly altered 6 h after LPS injection (Fig. 7a).
LPS (0.1 μg) being a submaximal dose, we have then
used higher concentrations of LPS, but no changes of
CD68 mRNA have been detected at any LPS dose
(Additional file 5: Figure S5). In contrast to those ex-
pression studies, immunostaining showed an increase
in CD68 protein abundance following LPS stimulation
in both Tollip WT and KO mice, with a 67% increase
of the number of CD68-positive cells in the LPS-
injected side in KO mice as compared with WT mice
(P < 0.001, Fig. 7b, c). Iba1 immunostaining was also
increased in the injected side in Tollip WT and KO mice
(P < 0.01), with a 39% increase of Iba1-positive cells in the
LPS-injected side in KO mice as compared with WT mice
(Fig. 7b, c). As for iNOS, nitrotyrosine, and 8-oxo-dG
markers, CD68 and Iba1 stainings in the side contralateral
to the LPS injection were higher in Tollip KO than in Tol-
lip WT mice (P < 0.05 and P < 0.001, respectively).
No astroglial activation, as measured by quantifying
GFAP mRNA, was observed in both genotypes (data not
shown).
In conclusion, the mRNA expression of microglia
markers was not significantly altered at 6-h post-
injection of LPS (0.1 μg) in either of the genotypes, and
no polarization of macrophages/microglia toward M1 or
M2 subtypes was observed. Nevertheless, the CD68 and
Iba1 immunostainings indicated higher microglia activa-
tion in Tollip KO mice as compared with Tollip WT
mice, suggesting a higher reactivity of Tollip KO mice to
LPS challenge.
Discussion
We report in this study a distinctive high density of
Tollip protein in dopaminergic neurons of the SNc and
Fig. 7 Acute microglial response to LPS. a Eleven-month-old female mice underwent PBS (1 μL) or LPS (0.1 μg) injection (n = 7 and n = 8 respectively
for WT mice and n = 6 and n = 12 respectively for the Tollip KO mice). mRNA amounts in midbrain extracts were normalized by β-actin and GAPDH.
b Representative CD68 and Iba1 immunostainings in non-injected (left) and LPS (0.1 μg)-injected side (right) in WT and Tollip KO 15-month-
old male mice. Magnification = ×40. Scale bar = 30 μm. c Quantification of CD68 and Iba1-positive cells, performed on two fields in the
injected area, on three sections per animal (n = 4 in WT and 5 mice in KO group). Results are represented as box and whiskers that show
median, min., and max. values, 25th and 75th percentiles. Plots represent individual values and means are represented as a “+.” #P < 0.05; ##P < 0.01;
###P < 0.001 versus non-injected side and *P < 0.05; ***P < 0.001 versus WT mice. Two-way ANOVA followed by a Tukey’s post hoc test
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VTA. This novel observation suggests that in spite of be-
ing ubiquitous in the brain, Tollip may play a major role
in dopaminergic cells. This result was unpredictable
from previous studies on human brain in which Tollip
mRNA was detected in SNc but not in a larger amount
relative to other structures [55, 56]. Thus, exploring the
impact of Tollip in dopaminergic neurons appears of
primary importance. Therefore, the effect of the absence
of the Tollip gene on the inflammatory response to a
LPS challenge in the mice SNc was studied.
In the current study, we used LPS at a one order of
magnitude lower dose than previously described in
models of PD [22, 23, 57]. Indeed, in chronic diseases, a
very low-grade endotoxemia can lead to systemic inflam-
mation [58]. Accordingly, in the brain, an acute low-
dose LPS challenge was shown to induce a long-term
sustained inflammatory state which can potentiate
alpha-synuclein dysfunction in an animal model of PD
[13]. Consequently, a low LPS dose is more likely to re-
capitulate a clinically relevant situation in which a mild
inflammatory stimulus becomes deleterious in a context
of increased susceptibility.
Our results show that Tollip controls LPS-mediated
inducible NO synthase (iNOS) quantities. This was asso-
ciated with a global tendency of increased cytokine in-
duction in the absence of Tollip. This inflammatory
response is in accordance with a TLR4-mediated acute
inflammation in the brain [59]. Tollip has already been
described as a negative regulator of TLR4 signaling
[26, 27], modulating the early MyD88-dependent re-
sponse in vitro (for review [60, 61]) and leading to
decreased NF-κB activation. These observations sup-
port the idea that, as already observed in vitro in im-
mune cells, Tollip regulates the NF-κB signaling
pathway in the brain. Accordingly, we showed, using
an NF-κB-inducible viral vector, that activation of
NF-κB was higher in Tollip KO mice, presumably ac-
counting for this higher inflammatory response. Our
results suggest that insufficient Tollip expression may
lead to an increased vulnerability to an inflammatory
stimulus. Interestingly, Cribbs and colleagues reported
a decrease in Tollip mRNA expression in the brain of
aging humans and patients diagnosed with dementia
[31], suggesting that the inflammatory response may
be altered in the brain of these patients.
In our study, the inflammatory response to LPS likely
involved resident cells, since recruitment of peripheral
immune cells has been described to occur at later time
points [62, 63]. This hypothesis is consistent with the
fact that resident glial cells have been reported to ex-
press TLR4, the target of LPS, and iNOS [49, 51, 64].
iNOS activation as well as IL-1β, TNF-α, and IL-6 in-
creases is typically associated with activated microglia
with a M1-like phenotype. On the basis of mRNA
analysis, no obvious increase of glial activation markers
without any evidence for a shift toward M1 phenotype
have been observed 6-h post-LPS injection in both geno-
types. Contrarily to mRNA expression, CD68 and Iba1
protein analyses showed a stronger immunostaining in
the SNc upon LPS challenge as compared with the non-
injected side, in both genotypes. This discrepancy may
be due to differences in sample composition between
qPCR and immunohistological measurements. Indeed,
whereas midbrain extracts for qPCR were prepared from
large punches including but not limited to the SNc,
the quantification of immunostainings was restricted
to the SNc, thus allowing for more precision. Alterna-
tively, sex difference may explain this discrepancy. In
our studies, females and males have been respectively
used for mRNA and immunohistochemistry experi-
ments. Indeed, in a LPS-induced neurodegeneration
model, a higher sensitivity of males versus females
has been observed [65].
Moreover, the 6-h time point may be too early to de-
tect a robust microglial markers increase. Indeed, previ-
ous studies in rats showed increased CD68 and CD11b/c
[62] and CD11b and Iba1 immunostainings [63] at 12 or
15 h respectively but not at 5 h after intra-cerebral injec-
tion of LPS. Similarly, cortical GFAP markers were up-
regulated upon LPS injection at 24 h [50]. Thus, it
remains to be determined if in our study, a more robust
microglial and astrocytic activation could be detected at
later time points. In the present study, the fact that
microglia mRNA markers are not increased in Tollip
KO mice as compared to WT mice upon LPS challenge
may indicate that microglial cells participate but are not
the only contributor to increased inflammation suscepti-
bility. Additional mechanisms must be investigated.
LPS (0.1 μg) induced a larger increase in iNOS mRNA
and protein amounts in Tollip KO mice as compared
with WT mice. The iNOS enzyme generates high level
of NO that plays an important role as a host defense
mechanism [52]. However, in the presence of oxidative
stress, it interacts with the superoxide anion radicals
(O2
−) to generate the free radical peroxynitrite (OONO),
the main nitrating agent in vivo [66–68]. Interestingly,
in our experimental setting, the iNOS increase corre-
lated with an increase in nitrotyrosine immunostaining,
a widely used marker of peroxynitrite formation. The
deleterious effect of the cerebral nitric oxide release has
been extensively reviewed [69–71]. Notably, nitration af-
fects protein functions [72, 73] and a role of NO over-
production in PD patients was already suggested
30 years ago [16, 17, 74]. Therefore, the greater propen-
sity of Tollip KO mice to generate nitrosative stress indi-
cates that Tollip may constitute a potential target for
neuroprotective therapies aimed at reducing iNOS-
mediated damage.
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Tollip is also able to interact with a wide range of pro-
teins that are not directly implicated in the regulation of
TLR-mediated NF-κB pathway, and the fact that Tollip
deletion might elicit effects that are not directly related
to NF-κB activation cannot be ruled out. A recent study
revealed that Tollip promoted neuronal apoptosis fol-
lowing ischemia/reperfusion injury in rodents, by dir-
ectly inhibiting Akt signaling in a TLR-independent
manner [33]. In addition, Tollip is able to interact with
phosphoinositides, thus participating in membrane
trafficking [75]. Tollip is also thought to participate in
trafficking of ubiquitinated proteins through interac-
tions with its “coupling of ubiquitin conjugation to
endoplasmic reticulum degradation” (CUE) domain
[76]. Accordingly, Tollip was localized in senile pla-
ques in Alzheimer’s disease brain [77], which has
been associated with neuronal intranuclear inclusions
in a mouse model of Huntington disease [78] and
prevented toxicity of polyglutamine repeats in cultured
cells [79, 80]. Thus, Tollip, through its ubiquitin-binding
CUE domain, is proposed to have a critical function in au-
tophagic clearance of protein aggregates. Finally, two stud-
ies suggest a direct link between Tollip and mitochondria
[34, 81]. Interestingly, ubiquitination abnormality, protein
aggregates, and mitochondrial dysfunctions are cardinal
features of the PD pathogenesis [82, 83].
We did not observe an increase in Tollip transcripts
after LPS treatment at any dose. This data is consist-
ent with findings of Lo and colleagues who similarly
did not detect an increase of the major Tollip tran-
script after LPS treatment in mouse macrophages
[35]. Nevertheless, an increase in Tollip protein abun-
dance has been reported in vivo in murine brain after
ischemia/reperfusion injury [33] and in vitro in monocytic
cells after LPS challenge [45]. The later authors suggest
that LPS-induced post-transcriptional events may contrib-
ute to such effect and propose that LPS treatment stabi-
lizes endogenous Tollip protein, rather than promoting a
Tollip neo-synthesis.
Our results, which show that the lack of Tollip aggra-
vates the inflammatory response elicited by cerebral in-
fusion of LPS, constitute a first evidence for a role of
Tollip in the early phase of neuroinflammation. As
chronic inflammation has been implicated in PD patho-
genesis, the impact of Tollip deletion at later time points
after LPS administration remains to be evaluated.
Conclusions
Several pioneers’ studies have described Tollip as a
modulator of the TLR4 and IL-1β pathway in immune
cells, exerting an inhibitory action on NF-κB activation.
The results of our study show that Tollip deletion exac-
erbated iNOS production, protein nitration, and DNA
oxidation induced by LPS injection in the substantia
nigra, a structure affected in PD. These findings high-
light a critical role for Tollip in the early phase of TLR4-
mediated neuroinflammation. As brain inflammation is
known to contribute to PD, Tollip may be a potential
target to provide a neuroprotective effect by reducing
neuroinflammation. Surprisingly, a high abundance of
Tollip protein in dopaminergic neurons is herein de-
scribed for the first time. This high expression level may
reflect a tighter control of the NF-κB signal transduction
cascade in the substantia nigra, which is particularly vul-
nerable to neuroinflammation and oxidative stress. A
potential role for Tollip as a target for PD drug develop-
ment remains to be investigated.
Additional files
Additional file 1: Figure S2. No alteration of Tollip expression 6 h after
intra-nigral LPS injection. A. Up - position of the analyzed sections in the
Paxinos Atlas [84]. Down - representative Tollip (in green) and tyrosine
hydroxylase (TH) (in red) immunostainings and DAPI staining (in blue) in
the SNc. Magnification = ×20. Scale bar = 50 μm. B. Up - figure extracted
from Paxinos rat brain atlas showing the part of midbrain extracted
for all qPCR experiments. Down - Tollip mRNA amounts in midbrain
extracts normalized by β-actin and GAPDH. WT mice underwent PBS or LPS
(0.01 or 0.1 or 1 μg) injection (n = 3 WT mice per group). Results are
expressed as mean ± SEM. (TIF 6918 kb)
Additional file 2: Figure S1. No residual Tollip immunoreactivity in
Tollip KO mice. Representative Tollip (in green) and tyrosine hydroxylase
(TH) (in red), immunostainings and DAPI staining (in blue) in the SNc of
non-injected Tollip WT (panels A and B) and Tollip KO (panel C) mice.
Merged - co-localization of Tollip, TH, and DAPI. A. Magnification = ×20.
Scale bar = 50 μm. Insets show the region photographed in panel B. B–C
Magnification = ×63. Scale bar = 50 μm. Arrows indicate Tollip-positive
cells which are not co-labeled with TH. (TIF 15231 kb)
Additional file 3: Figure S3. LPS induces a dose-dependent increase of
the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α 6 h after injection. WT
mice underwent PBS or LPS (0.01 or 0.1 or 1 μg) injection (n= 3 mice per
group). mRNA amounts in midbrain extracts are normalized by β-actin and
GAPDH. Results are expressed as mean ± SEM, *P< 0.05 versus PBS group,
using a Kruskal–Wallis test followed by a Dunn’s post hoc test. (TIF 1059 kb)
Additional file 4: Figure S4. No induction of iNOS 6 h after PBS
injection in the midbrain of Tollip KO mice. A representative iNOS and
NeuN immunostaining in the midbrain in contralateral and ipsilateral side
of the PBS (1 μL) injection, in Tollip KO mice. Magnification = ×40. Scale
bar = 30 μm. (TIF 740 kb)
Additional file 5: Figure S5. LPS at three doses did not increase CD68
mRNA into the midbrain of WT mice, at 6-h post-injection. WT mice
underwent intra-nigral PBS or LPS (0.01 or 0.1 or 1 μg) injection (n = 3 WT
mice per group). mRNA amounts in midbrain extracts are normalized by
β-actin and GAPDH. Results are expressed as mean ± SEM. (TIF 327 kb)
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